Achilles Therapeutics plc (ACHL) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts ACHL Hot Sheet
Join SI Premium – FREE
Achilles Therapeutics plc (NASDAQ: ACHL) reported Q2 EPS of ($0.41), in-line with the analyst estimate of ($0.41).
For earnings history and earnings-related data on Achilles Therapeutics plc (ACHL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Robinhood Ventures Fund II opens at $22.50, IPO at $25
- Ideal Power (IPWR) Tops Q2 EPS by 2c
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
